Company intelligence / Profile preview
Omeros Corporation
Seattle, Washington, United Statesomeros.com ↗
- Ownership
- Public · OMER
- Employees
- ~200
- Development stage
- Phase 3
01
Overview
Omeros has developed multiple clinical-stage programs including narsoplimab for complement-mediated diseases. The company previously commercialized OMIDRIA, which was divested in 2021 for over $1 billion. Current pipeline includes multiple first-in-class drugs targeting complement system and CNS disorders.
- Therapeutic areas
- PsychiatryNephrologyImmunologyHematologyNeurologyInfectious Diseases
- Modalities
- Small-molecule therapeuticsProtein therapeuticsAntibody therapeutics
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Partnerships
National Institute on Drug Abuse (NIDA)National Institutes of Health (NIH)
04
Financials
- Market cap
- $1.2B
- Total revenue
- $0
- Enterprise value
- $1.2B
Beyond the preview
Go deeper on Omeros Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omeros Corporation.